Targeting virulence to prevent infection: To kill or not to kill?

Drug Discovery Today: Therapeutic Strategies

Volumn 1, Issue 4, 2004, Pages 483-489

  Alekshun, Michael N ^a   Levy, Stuart B ^a,b  

^a Transcept Pharmaceuticals Inc   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ACYLATED HOMOSERINE LACTONE ANTAGONIST; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; CHLORHEXIDINE GLUCONATE; ENDOSIALIDASE; ENZYME; ENZYME INHIBITOR; FURANONE DERIVATIVE; LIPOPEPTIDE; LYSIN; METRONIDAZOLE; ORGANIC COMPOUND; OXAZOLIDINONE DERIVATIVE; P 1025; PLACEBO; POLYMER; PROBIOTIC AGENT; PROTEIN TYROSINE PHOSPHATASE INHIBITOR; QUORUM SENSING PEPTIDE ANTAGONIST; SMALL MOLECULE INHIBITOR; SORTASE INHIBITOR; STREPTOGRAMIN; SYNTHETIC PEPTIDE; TOLEVAMER; TOXIN INHIBITOR; UNCLASSIFIED DRUG; VANCOMYCIN; VIRULENCE FACTOR;

ANTIMICROBIAL THERAPY; ARTICLE; BACTERIAL VIRULENCE; BACTERIOPHAGE; CLINICAL TRIAL; DRUG TARGETING; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; INFECTION; NONHUMAN;

EID: 10944257281     PISSN: 17406773     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddstr.2004.10.006     Document Type: Review

References (49)

1. D.M. Shlaes The abandonment of antibacterials: Why and wherefore? Curr. Opin. Pharmacol. 3 2003 470-473
2. B.B. Finlay S. Falkow Common themes in microbial pathogenicity revisited Microbiol. Mol. Biol. Rev. 61 1997 136-169
3. A.L. Cheung G. Zhang Global regulation of virulence determinants in Staphylococcus aureus by the SarA protein family Front Biosci. 7 2002 d1825-d1842
4. A.R. Hauser et al. PepA, a secreted protein of Pseudomonas aeruginosa, is necessary for cytotoxicity and virulence Mol. Microbiol. 27 1998 807-818
5. K. Skorupski R.K. Taylor Control of the ToxR virulence regulon in Vibrio cholerae by environmental stimuli Mol. Microbiol. 25 1997 1003-1009
6. Y. Flashner et al. Generation of Yersinia pestis attenuated strains by signature-tagged mutagenesis in search of novel vaccine candidates Infect. Immun. 72 2004 908-915
7. L.I. Kupferwasser et al. Acetylsalicylic acid reduces vegetation bacterial density, hematogenous bacterial dissemination, and frequency of embolic events in experimental Staphylococcus aureus endocarditis through antiplatelet and antibacterial effects Circulation 99 1999 2791-2797
8. L.I. Kupferwasser et al. Salicylic acid attenuates virulence in endovascular infections by targeting global regulatory pathways in Staphylococcus aureus J. Clin. Invest. 112 2003 222-233
9. M.B. Miller B.L. Bassler Quorum sensing in bacteria Annu. Rev. Microbiol. 55 2001 165-199
10. H. Wu et al. Synthetic furanones inhibit quorum-sensing and enhance bacterial clearance in Pseudomonas aeruginosa lung infection in mice J. Antimicrob. Chemother. 53 2004 1054-1061
11. M. Hentzer et al. Attenuation of Pseudomonas aeruginosa virulence by quorum sensing inhibitors EMBO J. 22 2003 3803-3815
12. G. Dell'Acqua et al. Suppression of drug-resistant Staphylococcal infections by the quorum-sensing inhibitor RNAIII-inhibiting peptide J. Infect. Dis. 190 2004 318-320
13. P. Mayville et al. Structure-activity analysis of synthetic autoinducing thiolactone peptides from Staphylococcus aureus responsible for virulence Proc. Natl. Acad. Sci. USA 96 1999 1218-1223
14. M. Mourez et al. Designing a polyvalent inhibitor of anthrax toxin Nat. Biotechnol. 19 2001 958-961
15. M.S. Sarac et al. Protection against anthrax toxemia by hexa- d -arginine in vitro and in vivo Infect. Immun. 72 2004 602-605
16. C. Montecucco et al. Stop the killer: How to inhibit the anthrax lethal factor metalloprotease Trends Biochem. Sci. 29 2004 282-285
17. I. Dell'Aica et al. Potent inhibitors of anthrax lethal factor from green tea EMBO Rep. 5 2004 418-422
18. F. Liang et al. Aurintricarboxylic acid blocks in vitro and in vivo activity of YopH, an essential virulent factor of Yersinia pestis, the agent of plague J. Biol. Chem. 278 2003 41734-41741
19. J.P. Sun et al. Crystal structure of the Yersinia protein-tyrosine phosphatase YopH complexed with a specific small molecule inhibitor J. Biol. Chem. 278 2003 33392-33399
20. N. Mushtaq et al. Prevention and cure of systemic Escherichia coli K1 infection by modification of the bacterial phenotype Antimicrob. Agents Chemother. 48 2004 1503-1508
21. A. Svensson et al. Design and evaluation of pilicides: Potential novel antibacterial agents directed against uropathogenic Escherichia coli Chembiochem 2 2001 915-918
22. Y.M. Lee et al. Targeting virulence for antimicrobial chemotherapy Curr. Opin. Pharmacol. 3 2003 513-519
23. A. Larsson et al. Quantitative studies of the binding of the class II PapG adhesin from uropathogenic Escherichia coli to oligosaccharides Bioorg. Med. Chem. 11 2003 2255-2261
24. J. Ohlsson et al. Discovery of potent inhibitors of PapG adhesins from uropathogenic Escherichia coli through synthesis and evaluation of galabiose derivatives Chembiochem 3 2002 772-779
25. C.S. Eden et al. Inhibition of experimental ascending urinary tract infection by an epithelial cell-surface receptor analogue Nature 298 1982 560-562
26. C.G. Kelly et al. A synthetic peptide adhesion epitope as a novel antimicrobial agent Nat. Biotechnol. 17 1999 42-47
27. W.J. Weiss et al. Effect of srtA and srtB gene expression on the virulence of Staphylococcus aureus in animal models of infection J. Antimicrob. Chemother. 53 2004 480-486
28. S.K. Mazmanian et al. Staphylococcus aureus sortase mutants defective in the display of surface proteins and in the pathogenesis of animal infections Proc. Natl. Acad. Sci. USA 97 2000 5510-5515
29. C.J. Scott et al. Irreversible inhibition of the bacterial cysteine protease-transpeptidase sortase (SrtA) by substrate-derived affinity labels Biochem. J. 366 2002 953-958
30. S.H. Kim et al. Inhibition of sortase, a bacterial surface protein anchoring transpeptidase, by beta-sitosterol-3-O-glucopyranoside from Fritillaria verticillata Biosci. Biotechnol. Biochem. 67 2003 2477-2479
31. K.B. Oh et al. Discovery of diarylacrylonitriles as a novel series of small molecule sortase A inhibitors J. Med. Chem. 47 2004 2418-2421
32. S.H. Kim et al. Inhibition of the bacterial surface protein anchoring transpeptidase sortase by isoquinoline alkaloids Biosci. Biotechnol. Biochem. 68 2004 421-424
33. S.W. Kim et al. Inhibition of the bacterial surface protein anchoring transpeptidase sortase by medicinal plants Biosci. Biotechnol. Biochem. 66 2002 2751-2754
34. R.B. Sartor Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: Antibiotics, probiotics, and prebiotics Gastroenterology 126 2004 1620-1633
35. M.I. Alvarez-Olmos R.A. Oberhelman Probiotic agents and infectious diseases: A modern perspective on a traditional therapy Clin. Infect. Dis. 32 2001 1567-1576
36. M. Silva et al. Antimicrobial substance from a human Lactobacillus strain Antimicrob. Agents Chemother. 31 1987 1231-1233
37. B. Sheil et al. Is the mucosal route of administration essential for probiotic function? Subcutaneous administration is associated with attenuation of murine colitis and arthritis Gut 53 2004 694-700
38. B.S. Gan et al. Lactobacillus fermentum RC-14 inhibits Staphylococcus aureus infection of surgical implants in rats J. Infect. Dis. 185 2002 1369-1372
39. C.B. Kurtz et al. GT160-246, a toxin binding polymer for treatment of Clostridium difficile colitis Antimicrob. Agents Chemother. 45 2001 2340-2347
40. S.B. Levy The challenge of antibiotic resistance Sci. Am. 278 1998 46-53
41. J.E. Darnell Jr. Transcription factors as targets for cancer therapy Nat. Rev. Cancer 2 2002 740-749
42. J.D. Dattelbaum et al. UreR, the transcriptional activator of the Proteus mirabilis urease gene cluster, is required for urease activity and virulence in experimental urinary tract infections Infect. Immun. 71 2003 1026-1030
43. G.A. Champion et al. A branch in the ToxR regulatory cascade of Vibrio cholerae revealed by characterization of toxT mutant strains Mol. Microbiol. 23 1997 323-331
44. S.N. Coulter et al. Staphylococcus aureus genetic loci impacting growth and survival in multiple infection environments Mol. Microbiol. 30 1998 393-404
45. C.E. Blue T.J. Mitchell Contribution of a response regulator to the virulence of Streptococcus pneumoniae is strain dependent Infect. Immun. 71 2003 4405-4413
46. J.P. Throup et al. A genomic analysis of two-component signal transduction in Streptococcus pneumoniae Mol. Microbiol. 35 2000 566-576
47. D. Hava A. Camilli Large-scale identificationof serotype 4 Streptococcus pneumoniae virulence factors Mol. Microbiol. 45 2002 1389-1406
48. L.R. Camacho et al. Identification of a virulence gene cluster of Mycobacterium tuberculosis by signature-tagged transposon mutagenesis Mol. Microbiol. 34 1999 257-267
49. C.C. Frota et al. The AraC family transcriptional regulator Rv1931c plays a role in the virulence of Mycobacterium tuberculosis Infect. Immun. 72 2004 5483-5486